Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Altimmune stock sinks on mixed ph. 2 MASH results for GLP-1 drug
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.
James Waldron
Jun 26, 2025 8:41am
Rivus weight loss drug shows MASH win, muscle-sparing potential
Jun 24, 2025 10:07am
Amgen's ph. 3 MariTide studies will ramp up dosing to quell nausea
Jun 24, 2025 9:59am
Zealand's dual agonist tied to 11% weight loss in phase 1b
Jun 18, 2025 3:00pm
Scholar Rock's SMA drug helps Zepbound patients retain muscle
Jun 18, 2025 9:10am
Turkish bank invests $39M in Harvard next-gen obesity antibodies
Jun 16, 2025 1:07pm
